We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

3401:TSETeijin Limited Analysis

Data as of 2026-06-12 - not real-time

¥1,638.50

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Teijin Limited is trading around ¥1,639, comfortably above its 20‑day and 50‑day moving averages (¥1,616 and ¥1,630) and well above the 200‑day average of ¥1,455, indicating a strong price momentum. The RSI sits near the neutral zone at 53 and the MACD histogram is positive, signaling short‑term bullish pressure despite a modest bearish MACD line. However, the discounted cash‑flow model places fair value near ¥1,680 while the current price implies a -16 % downside, suggesting the stock is overvalued on a fundamental basis. The forward P/E of 4.6 is dramatically lower than the industry average of 30.6, reflecting expectations of earnings recovery, yet trailing earnings remain negative and operating margins are in the red, raising concerns about profitability. The dividend yield of 3.05 % with a payout ratio around 45 % appears sustainable given solid free cash flow, but the high net debt (over ¥230 bn) and a debt‑to‑equity ratio above 90 % warrant caution. Volatility is elevated at over 37 % for the past month, though beta is low (0.27), indicating limited systematic risk. The market sentiment index shows “Extreme Greed,” which may be inflating the price beyond intrinsic value. In sum, Teijin shows technical strength and an attractive dividend, but fundamental overvaluation, weak profitability, and leverage constraints suggest a measured stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance level of ¥1,678
  • Technical bullish signals (MACD histogram positive)
  • Fundamental overvaluation relative to DCF

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward earnings upside with low forward P/E
  • Attractive dividend yield and payout ratio
  • Potential correction from overvalued pricing

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Diversified business lines across fibers, composites, and healthcare
  • High leverage and negative operating margins
  • Sustainable dividend providing income while profitability improves

Key Metrics & Analysis

Financial Health

Revenue Growth-14.50%
Profit Margin-10.08%
P/E Ratio4.6
ROE-21.78%
ROA0.83%
Debt/Equity91.26
P/B Ratio0.9
Op. Cash Flow¥98.7B
Free Cash Flow¥42.0B
Industry P/E30.6

Technical Analysis

TrendNeutral
RSI53.0
Support¥1,561.50
Resistance¥1,677.50
MA 20¥1,616.48
MA 50¥1,630.25
MA 200¥1,455.48
MACDBullish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair Value¥1,680.24
Target Price¥1,374.00
Upside/Downside-16.14%
GradeOvervalued
TypeBlend
Dividend Yield3.05%

Risk Assessment

Beta0.27
Volatility37.39%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.